Allergan price target raised to $230 from $202 at BMO Capital BMO Capital raised its price target for Allergan shares to $230 citing the company's better than expected Q2 results and improved guidance. BMO calls Allergan's cost-cutting program "quite dramatic" and says it should drive upside to earnings. The firm keeps an Outperform rating on the stock.
Actavis completes acquisition of Allergan Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.